Daunorubicin HCl

For research use only.

Catalog No.S3035 Synonyms: Daunomycin HCl

32 publications

Daunorubicin HCl Chemical Structure

CAS No. 23541-50-6

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 90 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Daunorubicin HCl has been cited by 32 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.
Targets
DNA synthesis [1]
(Cell-free assay)
20 nM(Ki)
In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. [1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. [2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
P388 leukemia cell line NH;qOI9EgXSxdH;4bYPDqGG|c3H5 M3\H[2NwdXCxdX7kJJdieyCndnHseYF1\WRiZn;yJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFB|OEigcIV2c2WvaXGgZ4VtdCCuaX7lMEBKSzVyPUOgcm0> NYrqW2txOTB2N{myPVc>
HL60 cells M{G3b2Z2dmO2aX;uJIF{e2G7 MVnJckB3cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCycn;sbYZmemG2aX;uJI9nKEiONkCgZ4VtdHNuIFnDOVA:OC5yMEWg{txO M3zEflEzQDd5NUmz
human epidermoid carcinoma cell line KB-3-1 M{f2emN6fG:2b4jpZ:Kh[XO|YYm= M1\0WGlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB4[XNiZY\hcJVifGWmIIXzbY5oKHSqZTDoeY1idiCncHnk[ZJud2mmIHPhdoNqdm:vYTDj[YxtKGyrbnWgT2IuOy1zLDDJR|UxRTdibl2= NXnsNFJLOTJ2NEO3OlM>
human K562 cells NX\pV4lZS3m2b4TvfIlkyqCjc4PhfS=> MnrKO|IhcA>? NIXMXG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBZXFRiYYPzZZktKEeLNUC9O{41KG6P MXyyNFU6OTZ5OB?=
Dx5 w/PSC cell lines MojRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXTnXJlpXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCGeEWge{9RW0NiY3XscEBtcW6nczD1d4lv\yCPVGSgZZN{[XluIFnDOVA:OTRibl2= NULrZlg{OTB4OUi0OFk>
MDA MB 361(mammary carcinoma cell line) MVfDfZRwfG:6aXRCpIF{e2G7 NGPNdVNVcGViY3;tdI92dmRid3HzJJRme3SnZDDmc5IhcW62cnHj[YxtfWyjcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBOTEFiTVKgN|YyMG2jbX3hdpkh[2G{Y3nuc41iKGOnbHygcIlv\SliZYjwdoV{e2mwZzDMZYNbKCikZYThMYdidGGldH;zbYRie2VrLDDJR|UxRTF5IH7N NITPO2gyODN7NUS5NC=>
human MDA-MB-231 cells MVnDfZRwfG:6aXRCpIF{e2G7 Mli1O|IhcA>? Mki2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAzKM7:TR?= NHPIW4UyQTl4OEK1PC=>
MES-SA uterine tumor cell lines MmfxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHsWpZrXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCPRWOtV2EhfXSncnnu[UB1fW2xcjDj[YxtKGyrbnXzJJV{cW6pIF3UWEBie3OjeTygTWM2OD1yLkCyNUDPxE1? NYHzO|huOTB4OUi0OFk>
murine L1210 leukemia cells M2DBWWZ2dmO2aX;uJIF{e2G7 MWXJcohq[mm2b4L5JIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYTDj[YxteyxiSVO1NF0{OCCwTR?= NY\VfZcyQTd|M{S4Ny=>
HL60 cells MlL4SpVv[3Srb36gZZN{[Xl? NE\wSGlKdiC4aYTyc{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlv\HWlZTDhdI9xfG:|aYOgbY4hUEx4MDDj[YxteyxiQVO1NF0xNjB2IN88US=> NYjwXmdZOTJ6N{e1PVM>
CCRF-CEM (human lymphoblastic leukemic) cells NUCyZXZwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XncGlvKH[rdILvJIdzd3e2aDDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgR2NTTi2FRV2gLIh2dWGwIHz5cZBpd2KuYYP0bYMhdGW3a3XtbYMqKGOnbHzzMEBKTDVyPUCuNFQh|ryP MlvIOlk2OTB2OR?=
mouse NIH/3T3 cells M2jBcWN6fG:2b4jpZ:Kh[XO|YYm= MoPhO|IhcA>? NFP4eJVKdnS{aX7zbYMh[3m2b4TvfIlkcXS7IHHnZYlve3Rid3ns[EB1gXCnIH3veZNmKE6LSD:zWFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkC0OEDPxE1? MUGxPFk2PDB2MB?=
human prostate cancer HTB-81 cells M1XQOGN6fG:2b4jpZ:Kh[XO|YYm= MUHDfZRwfG:6aXPpeJkhfGijdDDjZZV{\WRiYTC1NEUhemWmdXP0bY9vKGmwIHHid49z[mGwY3WgZZQhPDlyIH7tJIlvKGi3bXHuJJBzd3O2YYTlJINidmOncjDIWGIuQDFiY3XscJMhfXOrbnegUXRUKGG|c3H5MEBGSzVyPUCuNFU5KM7:TR?= MorjNVExOjB{OEW=
human breast carcinoma line cells MX\GeY5kfGmxbjDhd5NigQ>? MWTjc41xd3WwZDD3ZZMhfGW|dHXkJIlvKH[rdILvJIZweiCrbnjpZol1cW:wIHHjeIl3cXS7IHHnZYlve3RiYTDz[Y5{cXSrdnWgbJVu[W5iYoLlZZN1KGOjcnPpco9u[SCuaX7lJINmdGy|LDDJR|UxRTBwME[g{txO MYi5NlU5OzVz
MCF-7 cells MYfDfZRwfG:6aXRCpIF{e2G7 MVPDc41xd3WwZDD3ZZMhfGW|dHXkJIZweiCrdIOgeI95cWOrdImgZYdicW6|dDDoeY1idiCkcnXhd5Qh[2GwY3XyJINmdGy|KF3DSk04MSxiSVO1NF0xNjB4IN88US=> M{\UO|k2PDh6MkC=
human HT-29 cells M2f4Z2N6fG:2b4jpZ:Kh[XO|YYm= M{nCcVczKGh? MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjB5IN88US=> M3vU[FE6QTZ6MkW4
human uterine sarcoma cell line MES-SA MnzCR5l1d3SxeHnjxsBie3OjeR?= MXfJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KGW4YXz1ZZRm\CC3c3nu[{B1cGViaIXtZY4hfXSncnnu[UB{[XKlb33hJINmdGxibHnu[UBOTVNvU1GsJGlEPTB;MD6wO{DPxE1? NWG3[Y5OOTJ2NEO3OlM>
human MRC5 cells Ml3PVJJwdGmoZYLheIlwdiCjc4PhfS=> NV7ZOmpISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIJ6KFiWVDDhd5NigSxiSVO1NF0xNjB5ODFOwG0> MVqyOVQ3PzJ7MR?=
MDA435/LCC6 cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NHXlbYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JG1FSTR|NT;MR2M3KGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUCuNFc6KM7:TR?= NF3TXo4yPzF3NEWwOS=>
human A549 cells MkHRR5l1d3SxeHnjxsBie3OjeR?= NX;qXXZXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC4JO69VQ>? MnLZNVk6Pjh{NUi=
Jurkat T lymphocytes M3zod2N6fG:2b4jpZ:Kh[XO|YYm= MlPJR5l1d3SxeHnjbZR6KGGpYXnud5QhUnW{a3H0JHQhdHmvcHjvZ5l1\XNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFgzPiEQvF2= MkHyNVY{PjZ4MEK=
human DU145 cells NFLJbZZRem:uaX\ldoF1cW:wIHHzd4F6 MmfCO|IhcA>? NFnNUZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wPUDPxE1? M1i3UFIzOjZyMU[2
human MDA-MB-231 cells MYLQdo9tcW[ncnH0bY9vKGG|c3H5 MlHGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGK7IGjUWEBie3OjeTygTWM2OD1yLkC5NUDPxE1? NVP4Nnp7OjV2NkeyPVE>
human H1299 cells Mn;EVJJwdGmoZYLheIlwdiCjc4PhfS=> NHXT[4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFixNlk6KGOnbHzzJIJ6KFiWVDDhd5NigSxiSVO1NF0xNjB7NjFOwG0> MkDtNlU1Pjd{OUG=
human HL60 cells M2TXWWN6fG:2b4jpZ:Kh[XO|YYm= NXnuVG9OPDhiaB?= NF33OFVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSC2conwZY4h[my3ZTDzeIFqdmmwZz3iZZNm\CCqZX3vZ5l1d22ndILpZ{BidmGueYPpd{whT0l3ME2wMlEh|ryP NVXCOnZTOjV6N{SzN|U>
human LNCAP cells MnfFR5l1d3SxeHnjxsBie3OjeR?= NEfEXHY1KGSjeYO= MXjDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD1yLkGg{txO NWrq[2VQOjJ2OEC0PVU>
NCI-H69 cell line MYPQdo9tcW[ncnH0bY9vKGG|c3H5 MoHJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHOnboPpeIl3\SCQQ1mtTFY6KGOnbHygcIlv\SCkeTDBcIFu[XJiQnz1[UBie3OjeTygTWM2OD1yLkGg{txO MlHPNVczQDZ|OUO=
human A2780 cells MU\DfZRwfG:6aXRCpIF{e2G7 NH\U[3o4OiCq MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVE4PDlizszN NXr6VFRtOTd6OUCwPVQ>
human HT-29 cells MlTwVJJwdGmoZYLheIlwdiCjc4PhfS=> NIrEWXk6PiCq MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zM{Og{txO NUTvXIh7Ojd5OES0PS=>
B16 mouse melanoma cells Mm\WR5l1d3SxeHnjxsBie3OjeR?= MUPDfZRwfG:6aXPpeJkhfGijdDDjZZV{\WRiYTC1NEUhemWmdXP0bY9vKGmwIHHid49z[mGwY3WgZZQhPDlyIH7tJIlvKEJzNjDtc5V{\SCvZXzhco9u[SClZXzsd{B2e2mwZzDNWHMh[XO|YYmsJGVEPTB;MD6xOkDPxE1? M1LERVEyODJyMki1
human SKMES1 cells NFH4bGxRem:uaX\ldoF1cW:wIHHzd4F6 MYm3NkBp MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONTVXTNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMUeg{txO NEOxRoUzOjJ4MEG2Oi=>
human fibroblast (NHF) cells NXXRN5FkS3m2b4TvfIlkyqCjc4PhfS=> MUnDfZRwfG:6aXPpeJkhfGijdDDjZZV{\WRiYTC1NEUhemWmdXP0bY9vKGmwIHHid49z[mGwY3WgZZQhPDlyIH7tJIlvKG6xcn3hcEBpfW2jbjDmbYJzd2KuYYP0JEhPUEZrIHPlcIx{KHW|aX7nJG1VWyCjc4PhfUwhTUN3ME2wMlIzKM7:TR?= MUCxNVAzODJ6NR?=
mouse L1210 cells NXTubYNMTnWwY4Tpc44h[XO|YYm= NV6yWnFGUW6qaXLpeIlwdiCxZjDSUmEhe3mwdHjld4l{KGmwIH3veZNmKExzMkGwJINmdGy|LDDFSFUxRTBwMkOg{txO NEji[Wo3QTB7OUm=
human NCI-H460 cells NXnjW2M1TnWwY4Tpc44h[XO|YYm= NUGxbpdrSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy|LDDJR|UxRTBwM{ig{txO Mn2zNlE2QTlyMEC=
human MCF7 cells Mlz4R5l1d3SxeHnjxsBie3OjeR?= MWW0JIRigXN? NH\meZNEgXSxc4TheIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOEDPxE1? NWrWfHRxOjJ2OEC0PVU>
human SF268 cells Mn\aSpVv[3Srb36gZZN{[Xl? NGDqZY5CdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMtKEmFNUC9NE43KM7:TR?= NYH2WnI4OjF3OUmwNFA>
human KB cells Ml\hR5l1d3SxeHnjxsBie3OjeR?= MnjXOFghcA>? MnLMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLk[0JO69VQ>? M2HENlIxOzZ|MUSy
human HepG2 cells NX3GVYk{S3m2b4TvfIlkyqCjc4PhfS=> MoS1NlQhcA>? MkfmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlch|ryP MV[yNVA6PDB2OR?=
mouse L5178Y cells NETKfWxEgXSxdH;4bYPDqGG|c3H5 MnjCNlQhcA>? MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMOVE4QFliY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlczKM7:TR?= M3nHTlI{OTl7NEe5
human MCF7 cells M4jLWGN6fG:2b4jpZ:Kh[XO|YYm= MX[3NkBp M4jJUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHhVXCCjc4PhfUwhT0l3ME2wMlg3KM7:TR?= MoLoNlA2QTF4N{i=
human MRC5 cells MVHQdo9tcW[ncnH0bY9vKGG|c3H5 NFiwSYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3SR|Uh[2WubIOsJGlEPTB;MD64PEDPxE1? MlzaNlE2QTlyMEC=
MDA435/LCC6 cells M{fEVHBzd2yrZnXyZZRqd25iYYPzZZk> NF\uXnpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI12dHSrZIL1[{Bz\XOrc4ThcpQhVUSDNEO1M2xESzZiY3XscJMh[nliRVzJV2EtKEmFNUC9NE46PzdizszN MUSxO|E2PDVyNR?=
mouse NIH/3T3 cells MYXDfZRwfG:6aXRCpIF{e2G7 MnvYO|IhcA>? MWHJcpRzcW6|aXOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCxdnXy[ZhxemW|c3nu[{BOTFJzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5yMTFOwG0> M2L2T|E5QTV2MESw
human Detroit 551 cells NIjzUJZEgXSxdH;4bYPDqGG|c3H5 M4KwVVczKGh? NHP2bWNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBF\XS{b3n0JFU2OSClZXzsd{Bi\nSncjC3NkBpenNiYomgXHRVKGG|c3H5MEBIUTVyPUGuO|ch|ryP NUnsOIlnOjB3OUG2O|g>
mouse DA-3 cells NVTVOplwS3m2b4TvfIlkyqCjc4PhfS=> NXG5bmZQOjRiaB?= NGjyd4pEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBFSS1|IHPlcIx{KGGodHXyJFI1KGi{czDifUBZXFRiYYPzZZktKEmFNUC9NU46KM7:TR?= NUPlbW1OOjR7MEC2Olg>
african green monkey Vero cells MorBR5l1d3SxeHnjxsBie3OjeR?= NHr5Slg{KGSjeYO= NECyPWhEgXSxdH;4bYNqfHliYXfhbY5{fCCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;Mj61JO69VQ>? MkHzNlExQTRyNEm=
Dx5 cell lines M4XFNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zTZnRp\SClb33wc5Vv\CC5YYOg[ZZidHWjdHXkJIZweiC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhTHh3IHPlcIwhdGmwZYOgeZNqdmdiTWTUJIF{e2G7LDDpZ|UxRTJizszN M4DJOFExPjl6NES5
human HeLa3 cell line MmH5R5l1d3SxeHnjxsBie3OjeR?= NUTIb4xTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYUOgZ4VtdCCuaX7lJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjl4IN88US=> NFPR[m8yPjl2MkCzOy=>
mouse L5178Y cells NH64NWhEgXSxdH;4bYPDqGG|c3H5 MoSyNlQhcA>? NIjRcppEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNPTF5OGmgZ4VtdHNiZYjwdoV{e2mwZzDwMYdxKGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{44OyEQvF2= M4nOVlI{OTl7NEe5
human CRL7761 cells NHHIOIREgXSxdH;4bYPDqGG|c3H5 NXPaclB5OyCmYYnz NInwcWtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEWkx5N{[xJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OTBwNTFOwG0> M1\1fFIyODl2MES5
human A2780/ADR cells M1jwNGN6fG:2b4jpZ:Kh[XO|YYm= MYW3NkBp MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OC:DRGKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQC54MkC5JO69VQ>? NVf1N5N6OTd6OUCwPVQ>
human SKOV3 cells NFXoVIpEgXSxdH;4bYPDqGG|c3H5 NFHOTogzPCCq MoTmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHhVXCCjc4PhfUwhUUN3ME2yNE43KM7:TR?= MVyyOFkxODZ4OB?=
human ES2 cells MXrDfZRwfG:6aXRCpIF{e2G7 MlHjNlQhcA>? MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDFV|Ih[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IGjUWEBie3OjeTygTWM2OD1{NT61JO69VQ>? M{HGSVI1QTByNk[4
CEM cells MXjDfZRwfG:6aXRCpIF{e2G7 NEHqTY04OiCq M1TOS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEOHTTDj[YxteyCjZoTldkA4OiCqcoO= NXOxZpd7OTd4MEizPVY>
HOS cells MVLDfZRwfG:6aXRCpIF{e2G7 M1LNR|czKGh? M1GyXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiRUzDj[YxteyCjZoTldkA4OiCqcoO= M4rp[|E4PjB6M{m2
mouse DA-3 cells NXzCRVBZS3m2b4TvfIlkyqCjc4PhfS=> NVPn[HNEOjBizszN MU[2NEBucW6| M3;vZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGRCNTNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFIxKHWPIHHmeIVzKDZyIH3pcpMh[nliWGTUJIF{e2G7 M3LqNlI1QTByNk[4
human G361 cells M4nCe2N6fG:2b4jpZ:Kh[XO|YYm= NUPPNGdtPzJiaB?= NV74c2F4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTzN4MTDj[YxteyCjZoTldkA4OiCqcoO= MYWxO|YxQDN7Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / p-ATR / ATR ; 

PubMed: 26727128     


After Caco-2 cells were treated with or without 1 μ M daunorubicin, whole cell extracts were collected at 1, 3, 6, 12, 24, and 48 h and immunoblotted for Chk1, p-Chk1, ATR, and p-ATR. β-actin served as the loading control.

26727128
Immunofluorescence
p-Chk1; 

PubMed: 26727128     


Caco-2 cells were treated with or without 1 μ M daunorubicin for 48 h, and then fixed and stained with anti-p-Chk1 antibody and DAPI. Images were collected under a fluorescence microscope. Scale bar = 10 μm. 

26727128
Growth inhibition assay
Cell viability; 

PubMed: 30745844     


(A) Viability of AML cell lines under different concentrations of Dnr according to the CCK-8 assay. (B) IC50 of AML cell lines calculated according to the result of the CCK-8 assay.

30745844

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (177.31 mM)
Water 100 mg/mL (177.31 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 563.98
Formula

C27H29NO10 . HCl

CAS No. 23541-50-6
Storage powder
in solvent
Synonyms Daunomycin HCl
Smiles CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03878927 Suspended Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT02914977 Active not recruiting Drug: Daunorubicin Acute Lymphocytic Leukemia|Acute Myeloid Leukemia Tara Lin|University of Kansas Medical Center November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Daunorubicin HCl | Daunorubicin HCl supplier | purchase Daunorubicin HCl | Daunorubicin HCl cost | Daunorubicin HCl manufacturer | order Daunorubicin HCl | Daunorubicin HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID